

(12) **United States Patent**  
**Cooke**

(10) **Patent No.:** **US 7,452,916 B2**  
(45) **Date of Patent:** **\*Nov. 18, 2008**

(54) **ENHANCEMENT OF VASCULAR FUNCTION BY MODULATION OF ENDOGENOUS NITRIC OXIDE PRODUCTION OR ACTIVITY**

(75) Inventor: **John P. Cooke**, Palo Alto, CA (US)

(73) Assignee: **The Board of Trustees of the Leland Stanford Junior University**, Palo Alto, CA (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/019,118**

(22) Filed: **Dec. 22, 2004**

(65) **Prior Publication Data**

US 2006/0009407 A1 Jan. 12, 2006

**Related U.S. Application Data**

(63) Continuation of application No. 10/618,835, filed on Jul. 15, 2003, now abandoned, which is a continuation of application No. 10/060,252, filed on Feb. 1, 2002, now Pat. No. 6,646,006, which is a continuation of application No. 09/930,833, filed on Aug. 15, 2001, now Pat. No. 6,642,208, which is a continuation of application No. 09/075,509, filed on May 8, 1998, now Pat. No. 6,337,321, which is a continuation of application No. 08/556,035, filed on Nov. 9, 1995, now Pat. No. 5,891,459, which is a continuation-in-part of application No. 08/336,159, filed on Nov. 8, 1994, now abandoned, which is a continuation-in-part of application No. 08/076,312, filed on Jun. 11, 1993, now Pat. No. 5,428,070.

(51) **Int. Cl.**  
*A23L 1/305* (2006.01)  
*A61K 9/00* (2006.01)

*A61K 31/198* (2006.01)  
*A61K 38/44* (2006.01)  
(52) **U.S. Cl.** ..... **514/565**; 424/94.4; 424/439; 424/441; 426/648; 426/656  
(58) **Field of Classification Search** ..... None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,878,124 A 3/1959 Krulkenberg

(Continued)

FOREIGN PATENT DOCUMENTS

EP 0 259 167 A2 3/1988

(Continued)

OTHER PUBLICATIONS

Castillo et al. Proceedings of the National Academy of Science USA. vol. 90, No. 1, pp. 193-197.\*

(Continued)

*Primary Examiner*—Jeffrey E Russel  
(74) *Attorney, Agent, or Firm*—Foley & Lardner LLP

(57) **ABSTRACT**

Endothelial nitric oxide production is enhanced by administration of arginine or lysine as a dietary supplement. Enhanced nitric oxide production from arginine supplementation improves vascular function and structure. Additional compounds may be administered with arginine or lysine to further enhance nitric oxide activity, including calcium, vitamin B6, vitamin B12, vitamin C, vitamin B, coenzyme Q, carotene, or glutathione.

**7 Claims, 14 Drawing Sheets**

